Atezolizumab (Tecentriq)
Immunotherapy · Approved since 2016
Description
Atezolizumab is a monoclonal antibody immunotherapy agent that blocks the PD-L1 checkpoint pathway to enhance immune system recognition of cancer cells. In colorectal cancer, it is primarily being utilized in combination regimens for metastatic disease, particularly in microsatellite stable (MSS) tumors when combined with chemotherapy and bevacizumab, and in patients with high immune cell infiltration. The drug is also being explored in combination with stereotactic body radiation therapy for MSS metastatic colorecral cancer and in patients with circulating tumor DNA-positive gastrointestinal cancers.
Mechanism of Action
Atezolizumab binds to programmed death-ligand 1 (PD-L1) expressed on tumor cells and tumor-infiltrating immune cells, preventing interaction with PD-1 and B7.1 receptors on T-cells. This blockade removes the inhibitory signals that normally suppress T-cell activation, allowing cytotoxic T-lymphocytes to recognize and attack cancer cells more effectively.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Tecentriq |
| Category | Immunotherapy |
 Status | FDA Approved |
 EMA Status | EMA Approved |
 Spain Access | Hospital use off-label in CRC |
| Administration | IV |
| Year Approved | 2016 |
| Clinical Trials | 45 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.